NeoGenomics, Inc. revised earnings guidance for the full year ending December 31, 2023. For the year, the company expected consolidated revenue to be in the range of $585 million to $592 million against the previous guidance range of $565 million to $575 million. Net loss to be in the range of $95 million to $89 million against the previous guidance range of $107 million to $100 million.